Introduction
============

Type 2 diabetes and metabolic syndrome are prevalent worldwide ([@b1-ijmm-38-06-1759]). These metabolic disorders are characterized by the disruption of glucose and lipid metabolism. Obesity is major risk for the development of type 2 diabetes and related metabolic disorders ([@b2-ijmm-38-06-1759]). The prevalence of obesity has increased worldwide, with more than a billion adults being overweight and over 300 million adults being classified as obese ([@b3-ijmm-38-06-1759]). Obesity is defined not as an excess of body weight, but as an excessive accumulation of fat mass in white adipose tissue to the extent that health may be adversely affected.

The accumulation of body fat greatly depends on adipocyte differentiation, also known as adipogenic differentiation or adipogenesis ([@b4-ijmm-38-06-1759]). Adipocyte differentiation is a complex process which is divided into four steps, including initial growth arrest, mitotic clonal expansion (MCE), early differentiation and terminal differentiation, namely the development of the mature adipocyte phenotype ([@b5-ijmm-38-06-1759],[@b6-ijmm-38-06-1759]). Adipocyte differentiation is regulated by a series of signaling pathways triggered by an adipogenic stimulus. Among these factors, peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer-binding protein (C/EBP)α family members are the key transcription factors responsible for adipogenesis ([@b7-ijmm-38-06-1759],[@b8-ijmm-38-06-1759]). In response to adipogenic stimuli, C/EBPβ is rapidly activated and functions at the early stage of differentiation by initiating the MCE of pre-adipocytes and activating the PPARγ and C/EBPα regulatory network ([@b9-ijmm-38-06-1759]--[@b12-ijmm-38-06-1759]). C/EBPα and PPARγ mutually interact and form a positive feedback loop that plays pivotal roles during the later stage of adipocyte differentiation by inducing and maintaining the expression of multiple adipocyte-specific genes, i.e. fatty-acid binding protein (aP2), cluster of differentiation 36 (CD36, a receptor for lipoproteins) and fatty acid transport protein-1 (FATP-1) ([@b13-ijmm-38-06-1759]--[@b16-ijmm-38-06-1759]). Abnormal adipocyte differentiation is involved in the development of multiple metabolic disorders.

Over the past years, many researchers have focused on the investigation of dietary agents and natural products that can be used for the intervention of metabolic disorders. Amentoflavone (AMF) is a polyphenolic compound derived from the extracts of *Selaginella tamariscina* which has been found to possess potent anti-inflammatory effects ([@b17-ijmm-38-06-1759]--[@b20-ijmm-38-06-1759]). A previous study demonstrated that AMF inhibits protein tyrosine phosphatase 1B activity, which has been proposed as a strategy for the treatment of type 2 diabetes and obesity ([@b21-ijmm-38-06-1759]). The present study was designed to examine the effects of AMF on high fat (HF) diet-induced metabolic dysfunction, focusing on the regulation of adipocyte differentiation.

Materials and methods
=====================

Materials
---------

Anti-β-actin (sc-130656), anti-PPARγ (sc-7273), anti-C/EBPα (sc-61) and anti-C/EBPβ (sc-746) antibodies and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). AMF, Oil Red O, insulin, 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA), N-acetylcysteine (NAC) and most of the chemicals and reagents used in this study were procured from Sigma (St. Louis, MO, USA).

Animal experiments
------------------

All animal experiments were performed according to the procedures approved by the Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing, China (approval no. CAMS-2014-12-115). A total of 32 male Wistar rats (6--8 weeks old; weighing 180--220 g) were purchased from the Animal Centre of Capital Medical University, Beijing, China. The rats were housed under controlled temperature (23±2°C) and humidity (55±5%) conditions with a standard light and dark (12 h light/dark) cycle. The rats were randomly divided into 4 groups as follows: the control group, the HF diet group, the HF diet + 10 mg/kg AMF group and the HF diet + 50 mg/kg AMF group. The rats in the control group were fed a standard diet (22% protein, 63% carbohydrate and 5% fat; Animal Center of Chinese Academy of Medical Sciences). The rats in the HF diet group were given a HF diet. The HF diet consisted of 10% protein, 72% carbohydrate and 8% fat; (Animal Center of Chinese Academy of Medical Sciences). Rats in HF diet + AMF group were administrated with 10 or 50 mg/kg/day AMF via intraperitoneal injection (AMF was dissolved in DMSO and diluted in saline) for 4 months. The experimental period lasted for 4 months. After being fed the different diets, fasting blood glucose (FBG) levels (12 h) were measured. At the end of the experiment, the rats were weighed using a scale used for animals prior to anesthesia. The mice were anesthetized with sodium pentobarbital, perirenal adipose tissues were weighed (perirenal adipose tissues were cut using surgical scissors and weighed using a precision balance) and tissue and blood samples (obtained from the vena cava) were then harvested for the assays.

Intraperitoneal glucose tolerance test (IPGTT) and intraperitoneal insulin tolerance test (IPITT)
-------------------------------------------------------------------------------------------------

After the animals were fed the different diets, the IPGTT and the IPITT were performed as previously described ([@b22-ijmm-38-06-1759]). The rats were fasted for 12 and 4 h, respectively, and the blood samples were obtained from the tail vein for the detection of basal glucose levels. Subsequently, each rat was intraperitoneally injected with glucose (1 g/kg body weight), or insulin (0.75 U/kg body weight). Blood samples were obtained from the tail vein at 30, 60 and 120 min after the injection and were analyzed immediately for the glucose concentration. The area under curve (AUC) was calculated to determine the relative efficiency of AMF. In the IPGTT and IPITT tests, AUC was used to evaluate response to glucose and insulin load. AUC was calculated as: (glucose level at 0 min + glucose level at 30 min) ×0.5/2 + (glucose level at 30 min + glucose level at 60 min) ×0.5/2 + (glucose level at 60 min + glucose level at 120 min) ×1/2.

Biochemical analysis
--------------------

After being fed the different diets, the blood samples were harvested and serum was separated for the estimation of triglyceride (TG) levels (Nanjing Jiancheng Co., Nanjing, China) and insulin levels (Crystal Chem, Downers Grove, IL, USA) using commercial kits. The assays were conducted according to the manufacture\'s instructions. The TG content was determined according to the formation of quinonyl compounds and the absorbance at 510 nm was measured. Insulin was determined with the ultra-sensitive rat insulin ELISA kit. At the end of detection, the A450 and subtract A630 values were measured within 30 min and insulin concentrations were calculated using the standard curve. Homeostatic model assessment-insulin resistance index (HOMA-IR) is an index reflecting the insulin sensitivity. HOMA-IR was calculated as: (glucose level × insulin level)/22.5.

Cell culture and treatment
--------------------------

The 3T3-L1 pre-adipocytes were cultured and differentiation was induced as previously described ([@b23-ijmm-38-06-1759]). The 3T3-L1 pre-adipocytes were cultured in Dulbecco\'s modified Eagle\'s medium (DMEM) supplemented with 10% bovine calf serum, penicillin (100 U/ml), streptomycin (100 *µ*g/ml) and glutamine (292 *µ*g/l). The cells were maintained at 37°C in a humidified 5% CO~2~ atmosphere. AT 2 days post-confluence (day 0), the 3T3-L1 pre-adipocytes were stimulated with 0.5 mM IBMX, 1 *µ*M dexamethasone and 167 nM insulin in DMEM containing 10% fetal bovine serum (FBS) (also known as DMI differentiation induction medium) for 2 days (day 2). The cells were then incubated with 10% FBS/DMEM medium with 167 nM insulin for a further 2 days (day 4) and were then cultured in 10% FBS/DMEM medium for an additional 4 days (day 8). Following 8 days of differentiation, \>90% of the cells became mature adipocytes with lipid-filled droplets. For AMF treatment, indicated concentrations (1--10 *µ*g/ml) of AMF were added to the DMI induction medium for the indicated incubation time periods (2 days) maintained when the medium was changed.

Cell transfection
-----------------

The scramble plasmids, and the C/EBPα and PPARγ plasmids were synthesized (GeneChem, Shanghai, China). Transient transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. C/EBPα (500 ng), or PPARγ (500 ng) or their empty vectors were mixed with 4 *µ*l Lipofectamine 2000 (Invitrogen) in 400 *µ*l serum-free medium and placed at temperature for 20 min. The mixture was then added to the wells and incubated for 4--6 h. The medium was then changed to complete culture medium. The cells were transfected with the plasmids 2 days before confluence.

Determination of lipid accumulation
-----------------------------------

After the treatments, the adipocytes were fixed with 4% paraformaldehyde for 30 min and rinsed with water. Subsequently, the fixed cells were stained with Oil Red O staining solution (6 parts of saturated Oil Red O dye in isopropanol + 4 parts water) for 30 min. The cells were washed with water to remove the excess dye. Lipid accumulation in the cells was observed under a microscope (Olympus, Tokyo, Japan). The cells were then incubated with 4% Nonidet P-40 in isopropanol for 5 min to dissolve the stained oil droplets. The absorbance of the dye lipid complex was measured at 510 nm using a plate reader (Tecan, Männedorf, Switzerland).

Cell viability and proliferation
--------------------------------

Cell viability was examined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. A total of 0.5 mg/ml MTT was added to each well and incubated for 4 h. After aspiration of the supernatants, formazan crystals were dissolved using DMSO. The absorbance at 550 nm was measured using a plate reader (Tecan). Cell proliferation was determined using a CCK8 assay kit (Beyotime, Shanghai, China) according to the manufacturer\'s instructions. Cells were plated in 96-well culture plates. After the treatment, 10 *µ*l of the CCK-8 solution was added to each well and cells were cultured at 37°C for an additional hour. The absorbance at 450 nm was measured to evaluate cell proliferation (Tecan). The absorbance was detected at 570 and 450 nm, respectively, using a microplate reader (Bio-Rad Biosystems, Hercules, CA, USA).

Determination of reactive oxygen species (ROS) generation
---------------------------------------------------------

ROS were detected usng the specific probe, DCFH-DA, as previously described ([@b24-ijmm-38-06-1759]). After the treatments, the cells were incubated with 10 *µ*M DCFH-DA in the dark at 37°C for 30 min. After washing twice with PBS, the ROS levels were analyzed by flow cytometry (C6; BD Biosciences, San Jose, CA, USA).

RNA isolation and reverse transcription-quantitative PCR (RT-qPCR)
------------------------------------------------------------------

Total RNA was isolated from the cells using an RNA isolation kit (Tiangen, Beijing, China) according to the manufacturer\'s instructions. RNA (500 ng) was reverse transcribed into cDNA using the First Strand cDNA synthesis kit (Takara, Tokyo, Japan). Quantitative PCR (qPCR) was performed using SYBR-Green (Takara) in a real-time PCR system from Bio-Rad Biosystems. The primers used were as follows: PPARγ forward, 5′-ACA AGA GCT GAC CCA ATG-3′and reverse, 5′-CAT GAG GGA GTT AGA AGG-3′; aP2 forward, 5′-CGT TCT CTT TCT CCC TGT-3′ and reverse, 5′-TTG AAG GAA ATC TCG GTG-3′; CD36 forward, 5′-TTT GGA TCT TTG ATG TGC-3′ and reverse, 5′-TTT CCT TGG CTA GAT AAC-3′; C/EBPα forward, 5′-AGGTGCTGGAGTTGACCAGT-3′ and reverse, 5′-CAGCCTAGAGATCCAGCGAC-3′; β-actin forward, 5′-AGG CCA ACC GTG AAA AGA TG-3′ and reverse, 5′-TGG CGT GAG GGA GAG CAT AG-3′. The 2^−ΔΔCT^ method was used to measure gene expression compared with the endogenous control (β-actin). Amplification was performed with an initial step at 94°C for 5 min, followed by 40 cycles of denaturation at 94°C for 30 sec, annealing at 63°C for 30 sec, and then extension at 72°C for 10 sec.

Protein extraction and western blot analysis
--------------------------------------------

Total protein was extracted from the cells using RIPA lysis buffer according to the manufacturer\'s instructions. The cell lysates were washed with cold phosphate-buffered saline (PBS) and incubated on ice in lysis buffer for 30 min. The lysates were centrifuged at 20,000 × g for 30 min at 4°C and the protein concentrations in the supernatants were measured using a Bradford protein assay kit (Pierce, Rockford, IL, USA). Approximately 20 *µ*g of protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were then transferred onto PVDF membranes (Millipore, Billerica, MA, USA), and the membranes were then blocked with 8% non-fat milk. The membranes were incubated overnight at 4°C with the primary antibodies (anti-β-actin, anti-PPARγ, anti-C/EBPα and anti-C/EBPβ antibodies). After washing with TBST, the membranes was incubated with a horseradish peroxidase-conjugated secondary antibody (Cat. no. 32260; Pierce) at 37°C for 30 min. Protein bands were visualized by ECL and captured using a Bio-Rad Imaging System (Bio-Rad Biosystems).

Statistical analysis
--------------------

Results were expressed as the means ± SEM. Statistical analysis was carried out by one-way analysis of variance (ANOVA) followed by the Newmane Keuls multiple-comparison post hoc test using GraphPad Prism software. Data were considered statistically significant for p\<0.05.

Results
=======

AMF attenuates metabolic dysfunction in rats fed a HF diet
----------------------------------------------------------

In the present study, we first evaluated the effects of AMF on metabolic dysfunction in rats fed a HF diet. As shown in [Table I](#tI-ijmm-38-06-1759){ref-type="table"}, the FBG levels in the HF diet group were 118.5±12.8 mg/dl, which were significantly higher than those of the control group rats (65.9±6.3 mg/dl). The administration of AMF at 10 and 50 mg/kg significantly decreased the FBG levels to 101.1±9.7 and 82.9±8.1 mg/dl, respectively in the HF diet group rats. The HF diet markedly increased the fasting insulin levels from 1.5±0.4 (control group) to 4.3±0.6 ng/dl. The administration of 10 and 50 mg/kg AMF significantly decreased the fasting insulin levels to 3.2±0.5 and 2.8±0.4 ng/dl, respectively in the HF diet-fed rats. As also shown in [Table I](#tI-ijmm-38-06-1759){ref-type="table"}, the HOMA-IR value was increased from 0.5±0.2 to 8.6±2.7 in the rats fed the HF diet. The administration of 10 and 50 mg/kg AMF significantly inhibited the increase in the HOMA-IR value (5.7±1.1 and 3.2±2.3, respectively) in the HF diet-fed rats.

We also examined the effects of AMF on glucose and insulin tolerance in the HF diet-fed rats ([Table II](#tII-ijmm-38-06-1759){ref-type="table"}). In the HF diet group, following the injection of glucose, the glucose level increased from 128.1±5.1 to 183.3±5.4 mg/dl at 30 min and then decreased to 145.8±6.7 mg/dl at 120 min, which was significantly higher than that of the control group. In the 10 mg/kg AMF group, following the injection of glucose, the glucose level increased from 105.2±4.9 to 163.8±4.8 mg/dl at 30 min at 30 min and then decreased to 129.9±6.4 mg/dl at 120 min. In the 50 mg/kg AMF group, following the injection of glucose, the glucose level increased from 87.8±5.1 to 131.9±5.2 mg/dl at 30 min and then decreased to 116.5±6.6 mg/dl at 120 min. The glucose levels in the AMF groups were significantly lower than those of the HF-diet group, as indicated by the IPGTT. The AUC was calculated and the results revealed that AMF significantly inhibited the increase in the AUC value in the HF diet-fed rats, as indicated by the IPGTT.

As regards insulin tolerance, in the HF-diet group, following the injection of insulin, the glucose level decreased from 154.8±5.1 to 85.6±5.8 mg/dl at 60 min and then increased to 92.4±5.7 mg/dl at 120 min, which was significantly higher than that of the control group. In the 10 mg/kg AMF group, following the injection of insulin, the glucose level decreased from 125.6±5.4 to 68.9±5.6 mg/dl at 60 min and then increased to 75.8±5.1 mg/dl at 120 min. In the 50 mg/kg AMF group, following the injection of insulin, the glucose level decreased from 91.7±4.8 to 53.9±5.7 mg/dl at 60 min and then increased to 57.8±5.5 mg/dl at 120 min. The glucose levels in the AMF groups were significantly lower than those of the HF diet group, as indicated by IPITT. As shown by the AUC values, AMF significantly inhibited the increase in the AUC values in the HF diet-fed rats, as indicated by the IPITT. These results indicated that the administration of AMF significantly attenuated HF diet-induced metabolic dysfunction in rats.

AMF attenuates lipid accumulation in rats fed a HF diet
-------------------------------------------------------

A shown in [Table III](#tIII-ijmm-38-06-1759){ref-type="table"}, the HF diet significantly increased the body weights of the rats from 362±38 to 484±37 g. The administration of 10 and 50 mg/kg AMF significantly inhibited the HF diet-induced increase in body weight (434±29 and 402±25, respectively). We also determined the weights of perirenal adipose tissues and the results revealed that the weights of the perirenal adipose tissues were significantly increased in the HF diet group (13.8±3.9 g). The administration of 10 and 50 mg/kg AMF markedly decreased the weights of the perirenal adipose tissues to 10.2±1.6 and 8.3±2.5 g, respectively, in the HF diet-fed rats ([Table III](#tIII-ijmm-38-06-1759){ref-type="table"}). The serum TG content was also determined. As shown in [Table III](#tIII-ijmm-38-06-1759){ref-type="table"}, the HF diet induced a significant increase in the TG content (249±25 mg/dl). The administration of 10 and 50 mg/kg AMF significantly inhibited the increase in the serum TG content (211±15 and 176±14, respectively) in the rats fed the HF diet. These results indicated that the administration of AMF significantly attenuated HF diet-induced lipid accumulation in rats.

AMF inhibits 3T3-L1 adipocyte differentiation
---------------------------------------------

We examined the effects of AMF on 3T3-L1 adipocyte differentiation *in vitro*. AMF inhibited the accumulation of oil droplets in the differentiated adipocytes in a concentration-dependent manner, indicating that AMF suppressed 3T3-L1 adipocyte differentiation ([Fig. 1A and B](#f1-ijmm-38-06-1759){ref-type="fig"}). Moreover, we evaluated the effect of AMF on 3T3-L1 adipocyte differentiation during different stages of differentiation. 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 10 *µ*g/ml AMF for 0--8, 0--2, 2--4 and 4--8 days. As shown in [Fig. 1C](#f1-ijmm-38-06-1759){ref-type="fig"}, 0--2, 2--4 and 4--8 days of incubation of the cells with AMF significantly decreased Oil Red O staining in adipocytes, compared with the control, indicating that AMF exerted inhibitory effects on 3T3-L1 adipocyte differentiation at different stages of differentiation.

AMF inhibits MCE during 3T3-L1 adipocyte differentiation by promoting ROS generation
------------------------------------------------------------------------------------

To examine the effects of AMF on MCE, 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of indicated concentrations of AMF for 2 days and cell viability and proliferation were detected. AMF inhibited cell viability and proliferation in a concentration-dependent manner at day 2 of differentiation, indicating the suppression of MCE ([Fig. 2A and B](#f2-ijmm-38-06-1759){ref-type="fig"}). To examine the mechanisms resposible for the AMF-induced inhibition of MCE, the effect of AMF on C/EBPβ expression was determined. AMF inhibited the mRNA and protein expression of C/EBPβ in a concentration-dependent manner ([Fig. 2C and D](#f2-ijmm-38-06-1759){ref-type="fig"}). Moreover, we examined the effect of AMF on ROS generation during MCE. As shown in [Fig. 2E](#f2-ijmm-38-06-1759){ref-type="fig"}, at day 1 of differentiation, AMF markedly increased the ROS level in a concentration-dependent manner. Furthermore, AMF only increased the ROS level at the early stages of adipocyte differentiation, indicating that ROS generated by AMF mainly influence MCE ([Fig. 2F](#f2-ijmm-38-06-1759){ref-type="fig"}). A shown in [Fig. 2G and H](#f2-ijmm-38-06-1759){ref-type="fig"}, we found that the antioxidant, NAC, significantly suppressed the inhibitory effect of AMF on cell proliferation and oil droplet accumulation, confirming that ROS generation was involved in the AMF-induced inhibition of adipocyte differentiation through the suppression of MCE.

AMF inhibits 3T3-L1 adipocyte differentiation through the inhibition of C/EBPα/PPARγ signaling
----------------------------------------------------------------------------------------------

To evaluate the mechanisms responsible for the inhibitory effect of AMF on the early and terminal differentiation of 3T3-L1 adipocytes, the effects of AMF on C/EBPα and PPARγ expression were determined. AMF inhibited the mRNA and protein expression of C/EBPα and PPARγ in a concentration-dependent manner ([Fig. 3A--D](#f3-ijmm-38-06-1759){ref-type="fig"}). Moreover, we detected the expression of aP2 and CD36, which are direct targets of PPARγ in the regulation of adipogenic differentiation. The mRNA expression of aP2 and CD36 was significantly inhibited by AMF in a concentration-dependent manner ([Fig. 3E and F](#f3-ijmm-38-06-1759){ref-type="fig"}). To further examine the role of the downregulation of C/EBPα and PPARγ in the AMF-induced inhibition of adipocyte differentiation, 3T3-L1 pre-adipocytes were transfected with C/EBPα and PPARγ plasmids. As shown in [Fig. 2G and H](#f2-ijmm-38-06-1759){ref-type="fig"}, the overexpression of C/EBPα and PPARγ significantly prohibited the AMF-induced inhibition of adipocyte differentiation. These results indicated that AMF inhibited 3T3-L1 adipocyte differentiation through the inhibition of C/EBPα/PPARγ signaling.

Discussion
==========

AMF is a polyphenolic compound derived from the extracts of *Selaginella tamariscina*. A number of studies have demonstrawted that AMF exerts anti-inflammatory ([@b17-ijmm-38-06-1759]--[@b20-ijmm-38-06-1759]), antioxidant ([@b25-ijmm-38-06-1759]--[@b27-ijmm-38-06-1759]), anti-viral ([@b28-ijmm-38-06-1759],[@b29-ijmm-38-06-1759]) and antitumor effects ([@b30-ijmm-38-06-1759],[@b31-ijmm-38-06-1759]), as well as protective effects against radiation-induced damaqge ([@b32-ijmm-38-06-1759],[@b33-ijmm-38-06-1759]) and neuroprotective effects ([@b32-ijmm-38-06-1759],[@b33-ijmm-38-06-1759]). Na *et al* found that AMF inhibited protein tyrosine phosphatase 1B activity, implicating a potential use of AMF in the treatment of type 2 diabetes and obesity ([@b21-ijmm-38-06-1759]). In the current study, we evaluated the protective effects of AMF against metabolic dysfunction and focused on the influence of AMF on adipocyte differentiation.

We found that AMF protected against HF diet-induced metabolic dysfunction in a dose-dependent manner, as evidenced by a decrease in fasting blood glucose levels, fasting insulin levels, HOMA-IR and a decrease in the level of glucose (as shown by IPGTT and IPITT). Lipid accumulation and thus, obesity is the major contributor to metabolic disroders induced by a HF diet ([@b34-ijmm-38-06-1759],[@b35-ijmm-38-06-1759]). In the present study, we focused on whether the improvement of metabolic function induced by AMF was attributed to the regulation of lipid accumulation. We found that AMF significantly inhibited the increase in body weights, the weights of perirenal adipose tissues and the serum TG content in a dose-dependent manner in rats fed a HF diet. Our data demonstrated that the inhibition of lipid accumulation may be involved in the inhibitory effects of AMF on HF diet-induced metabolic dysfunction.

We then examined the possible mechanism responsible for the AMF-induced inhibition of lipid accumulation. The accumulation of body fat largely depends on adipocyte differentiation. The course of adipocyte differentiation includes four steps, initial growth arrest, MCE, early differentiation and terminal differentiation, namely the development of the mature adipocyte phenotype ([@b5-ijmm-38-06-1759],[@b6-ijmm-38-06-1759]). Our results revealed that AMF inhibited the different stages of adipocyte differentiation. MCE is a synchronous process required for adipogenesis ([@b36-ijmm-38-06-1759]). C/EBPβ is required for MCE during adipogenesis ([@b12-ijmm-38-06-1759]). We found that AMF decreased C/EBPβ expression in a concentration-dependent manner, leading to the inhibition of MCE. Moreover, our results indicated that ROS generation was involved in the AMF-induced inhibition of MCE. Hoever, it has been demonstrated that ROS enhance MCE and facilitate adipogenesis by promoting C/EBPβ expression ([@b37-ijmm-38-06-1759]). This discrepancy may be attributed to different levels or sources of ROS production. It has been demonstrated that AMF exhibits potential antioxidant activities ([@b25-ijmm-38-06-1759]--[@b27-ijmm-38-06-1759]). For example, Xu *et al* found the free radical scavenging and antielastase activities of AMF ([@b26-ijmm-38-06-1759]). Yamaguchi *et al* indicated that AMF from Brazilian pine *Araucaria angustifolia* exerted protective effects against DNA damage and lipoperoxidation ([@b27-ijmm-38-06-1759]). Combined with our results, it is suggested that AMF exerts differential effects on the redox state in different cell lines or under different conditions.

After MCE, early and terminal differentiation is mainly regulated by the PPARγ and C/EBPα interactive network. Without C/EBPα, the formation of white adipose tissue is disrupted ([@b38-ijmm-38-06-1759]). The ectopic expression of C/EBPα promotes adipogenesis in various fibroblastic cell lines ([@b39-ijmm-38-06-1759]). However, C/EBPα is incapable of inducing adipogenesis without PPARγ ([@b39-ijmm-38-06-1759]). PPARγ regulates adipocyte differentiation by transcriptionally modulating a battery of target genes responsible for the terminal maturation of fat cells, including aP2 and CD36. Our results indicated that AMF inhibited PPARγ and C/EBPα expression and the expression of downstream targets in a concentration-dependent manner. The overexpression of PPARγ and C/EBPα suppressed the AMF-induced inhibition of the formation of oil droplets, indicating that the downregulation of PPARγ and C/EBPα was involved in the AMF-induced inhibitory effect on adipocyte differentiation.

In conclusion, in the present study, we found that AMF attenuated metabolic dysfunction in HF diet-fed rats and exerted inhibitory effects on 3T3-L1 adipocyte differentiation ([Fig. 4](#f4-ijmm-38-06-1759){ref-type="fig"}). Furthermore, AMF promoted ROS generation, decreased C/EBPβ, resulting in inhibition of MCE; on the other way, AMF inhibited PPARγ and C/EBPα expression, suppressed molecular pathways that responsible for the formation of lipid droplets, leading to inhibition of early and terminal differentiation ([Fig. 4](#f4-ijmm-38-06-1759){ref-type="fig"}). The inhibitory effects on adipocyte differentiation may contribute to the protective effects of AMF against HF diet-induced metabolic dysfunction ([Fig. 4](#f4-ijmm-38-06-1759){ref-type="fig"}). Overall, the data from the present study provide novel insight into the mechanisms underlying the protective effects of AMF against metabolic dysfunction and the inhibitory effects of AMF on adipocyte differentiation.

![Effect of amentoflavone (AMF) on 3T3-L1 adipocyte differentiation. (A and B) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 1--10 *µ*g/ml AMF for 8 days. (A) After differentiation, lipid accumulation in adipocytes was examined by Oil Red O staining and observed under a microscope. (B) The oil droplets were then dissolved in isopropanol and the absorbance of the dyeetriglyceride complex was measured at 510 nm. The results are expressed as folds of DMI. (C) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation for 8 days with 10 *µ*g/ml AMF at 0--8, 0--2, 2--4 or 4--8 days. After differentiation, lipid accumulation in adipocytes was examined by Oil Red O staining and then dissolved in isopropanol and the absorbance of the dyeetriglyceride complex was measured at 510 nm. The results are expressed as folds of DMI. ^\*^p\<0.05 compared with DMI.](IJMM-38-06-1759-g00){#f1-ijmm-38-06-1759}

![Effect of amentoflavone (AMF) on mitotic clonal expansion (MCE) during 3T3-L1 adipocyte differentiation. (A and B) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 1--10 *µ*g/ml AMF for 2 days. Subsequently, (A) cell viability and (B) cell proliferation were determined and the results are shown as folds of DMI. (C--E) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 1--10 *µ*g/ml AMF for 24 h. Subsequently, the (C) mRNA and (D) protein expression of C/EBPβ was determined by RT-qPCR and western blot analysis, respectively. (E) Intracellular ROS levels were detected using the DCFH-DA probe and analyzed by flow cytometry. The results were shown as folds of DMI. (F) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 10 *µ*g/ml AMF for 1, 3, 5 and 7 days. Subsequently, intracellular ROS levels were determined and expressed as folds of increase compared to respective basal level at different differentiated stages. (G) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 10 *µ*g/ml AMF with or without 100 *µ*M N-acetylcysteine (NAC) for 2 days. Subsequently, cell proliferation was determined and the results were shown as folds of DMI. (H) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 10 *µ*g/ml AMF with or without 100 *µ*M NAC for 8 days. After differentiation, lipid accumulation in adipocytes was examined by Oil Red O staining and then dissolved in isopropanol and the absorbance of the dyeetriglyceride complex was measured at 510 nm. The results are expressed as folds of DMI. ^\*^p\<0.05 compared with DMI; ^\#^p\<0.05 compared with the AMF group.](IJMM-38-06-1759-g01){#f2-ijmm-38-06-1759}

![Effect of amentoflavone (AMF) on CCAAT/enhancer-binding protein α (C/EBPα)/peroxisome proliferator-activated receptor γ (PPARγ)-regulated adipocyte differentiation of 3T3-L1 cells. (A--F) 3T3-L1 pre-adipocytes were subjected to adipogenic differentiation in the presence of 1--10 *µ*g/ml AMF for 5 days. Subsequently, the (A and C) mRNA and (B and D) protein expression of C/EBPα and PPARγ was determined by RT-qPCR and western blot analysis, respectively. The mRNA expression of (E) aP2 and (F) CD36 was determined by RT-qPCR. (G and H) 3T3-L1 pre-adipocytes were transfected with C/EBPα or PPARγ plasmids 2 days before confluence. The cells were then subjected to adipogenic differentiation in the presence of 10 *µ*g/ml AMF for 8 days. After differentiation, lipid accumulation in adipocytes was examined by Oil Red O staining and then dissolved in isopropanol and the absorbance of the dyeetriglyceride complex was measured at 510 nm. The results are expressed as folds of DMI. ^\*^p\<0.05 compared with DMI; ^\#^p\<0.05 compared with the AMF group.](IJMM-38-06-1759-g02){#f3-ijmm-38-06-1759}

![Schematic diagram of the molecular mechanisms underlying the amentoflavone (AMF)-induced protective effects against adipogenic differentiation and metabolic dysfunction.](IJMM-38-06-1759-g03){#f4-ijmm-38-06-1759}

###### 

Effect of AMF on high fat diet-induced metabolic dysfunction.

  Group           FBG (mg/dl)                                                 FI (ng/dl)                                               HOMA-IR
  --------------- ----------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Control         65.9±6.3                                                    1.5±0.4                                                  0.5±0.2
  High-fat diet   118.5±12.8[a](#tfn1-ijmm-38-06-1759){ref-type="table-fn"}   4.3±0.6[a](#tfn1-ijmm-38-06-1759){ref-type="table-fn"}   8.6±2.7[a](#tfn1-ijmm-38-06-1759){ref-type="table-fn"}
  10 mg/kg AMF    101.1±9.7[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}    3.2±0.5[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}   5.7±1.1[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}
  50 mg/kg AMF    82.9±8.1[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}     2.8±0.4[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}   3.2±2.3[b](#tfn2-ijmm-38-06-1759){ref-type="table-fn"}

p\<0.05 compared with the control group;

p\<0.05 compared with the high-fat diet group. AMF, amentoflavone; FBG, fasting blood glucose levels; FI, fasting insulin levels.

###### 

Effect of AMF on high-fat diet-induced glucose and insulin intolerance.

  Group           IPGTT (mg/dl)                                                                                                                                                                                                                               
  --------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------
  Control         64.8±4.6                                                   118.2±5.8                                                  97.1±6.3                                                   77.4±5.5                                                   191±16
  High-fat diet   128.1±5.1[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}   183.3±5.4[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}   165.2±6.6[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}   145.8±6.7[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}   319±23[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}
  10 mg/kg AMF    105.2±4.9[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   163.8±4.8[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   145.6±5.3[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   129.9±6.4[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   285±18[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}
  50 mg/kg AMF    87.8±5.1[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    131.9±5.2[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   127.5±5.7[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   116.5±6.6[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   247±22[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}
                                                                                                                                                                                                                                                              
                  IPITT (mg/dl)                                                                                                                                                                                                                               
  Control         77.18±5.2                                                  51.3±5.3                                                   43.1±4.9                                                   44.7±5.4                                                   121±8
  High-fat diet   154.8±5.1[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}   97.9±6.6[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}    85.6±5.8[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}    92.4±5.7[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}    209±9[a](#tfn3-ijmm-38-06-1759){ref-type="table-fn"}
  10 mg/kg AMF    125.6±5.4[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}   79.5±4.7[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    68.9±5.6[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    75.8±5.1[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    184±7[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}
  50 mg/kg AMF    91.7±4.8[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    61.6±5.2[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    53.9±5.7[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    57.8±5.5[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}    149±8[b](#tfn4-ijmm-38-06-1759){ref-type="table-fn"}

p\<0.05 compared with the control group;

p\<0.05 compared with the high-fat diet group; AMF, amentoflavone; IPGTT, intraperitoneal glucose tolerance test; IPITT, intraperitoneal insulin tolerance test; AUC, area under the curve.

###### 

Effect of AMF on high fat diet-induced lipid accumulation.

  Group          BW (g)                                                  PATW (g)                                                  Serum TG (mg/dl)
  -------------- ------------------------------------------------------- --------------------------------------------------------- -------------------------------------------------------
  Control        362±38                                                  3.5±1.4                                                   146±21
  High fat       484±37[a](#tfn5-ijmm-38-06-1759){ref-type="table-fn"}   13.8±3.9[a](#tfn5-ijmm-38-06-1759){ref-type="table-fn"}   249±25[a](#tfn5-ijmm-38-06-1759){ref-type="table-fn"}
  10 mg/kg AMF   434±29[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}   10.2±1.6[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}   211±15[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}
  50 mg/kg AMF   402±25[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}   8.3±2.5[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}    176±14[b](#tfn6-ijmm-38-06-1759){ref-type="table-fn"}

p\<0.05 compared with the control group;

p\<0.05 compared with the high-fat diet group. AMF, amentoflavone; BW, body weight; PATW, perirenal adipose tissue weight; TG, triglyceride.

[^1]: Contributed equally
